The results of the Turkey R&D 250 research have been unveiled, identifying companies that achieved significant success in the field of research and development in 2022, providing a valuable reference both domestically and internationally. This year, the top 500 companies with the highest R&D expenditures have been disclosed and curated into a prestigious list. The Turkey R&D 250 research is based on the data from the top 500 companies in Turkey’s export rankings, firms that share their R&D data on the Public Disclosure Platform, and surveys conducted by R&D centers approved by the Ministry of Industry and Technology of the Republic of Turkey.

The core data for the Turkey R&D 250 research comprises R&D expenditures in 2022 and their proportion to total revenues, planned R&D expenditures for 2023, R&D personnel counts, the number of patents, utility models, design registrations, and trademarks obtained in R&D centers in 2022, as well as the ratio of R&D support acquired in 2022.

TriaTech Tıbbi Sistemler San. ve Tic. A.Ş., based in Izmir/Turkey and renowned for its investments in the STOCKART Automated Medication and Supply Management Systems brand, has made a significant impact by securing the 363rd position in the “2022 Second 250 Companies with the Highest R&D Expenditures” list. TriaTech is dedicated to producing high-tech, value-added, and competitive products, with a focus on reducing foreign dependence in the medical device sector, boosting employment, and enhancing customer satisfaction and loyalty through a combination of cost advantages and quality approaches. Additionally, TriaTech is committed to executing a global growth strategy to increase the visibility of the STOCKART brand abroad and contribute to positioning Turkey as an attractive hub. In the forthcoming years, they plan to further amplify their investments in research and development to achieve these goals.

Source: https://turkishtimedergi.com/arge250/2021/

Press Release ArGe250 2022